Compare · NVO vs RCUS
NVO vs RCUS
Side-by-side comparison of Novo Nordisk A/S (NVO) and Arcus Biosciences Inc. (RCUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RCUS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $211.73B, about 59.7x RCUS ($3.54B).
- RCUS has been more active in the news (12 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 16 for RCUS).
- Company
- Novo Nordisk A/S
- Arcus Biosciences Inc.
- Price
- -
- -
- Market cap
- $211.73B
- $3.54B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 3
- 12
- Recent ratings
- 25
- 16
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Arcus Biosciences Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RCUS
- SEC Form 144 filed by Arcus Biosciences Inc.
- Director Lambert Nicole was granted 5,700 shares, increasing direct ownership by 15% to 43,000 units (SEC Form 4)
- Director Kaneko Yasunori was granted 5,700 shares, increasing direct ownership by 28% to 25,700 units (SEC Form 4)
- Director Machado Patrick was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- General Counsel Tang Carolyn C. exercised 34,090 shares at a strike of $2.57, increasing direct ownership by 23% to 184,607 units (SEC Form 4)
- Director Lacey David L. was granted 5,700 shares, increasing direct ownership by 8% to 76,652 units (SEC Form 4)
- Director Ribas Antoni was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- Director Perlman Andrew J was granted 5,700 shares, increasing direct ownership by 13% to 48,325 units (SEC Form 4)
- Director Falberg Kathryn E was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- Arcus Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders